The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinus Disease, Olfaction, and the Sinonasal Microbiome in Patients with Cystic Fibrosis
Main Article Content
Abstract
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective triple modulator therapy that has significantly reduced morbidity and mortality in patients with cystic fibrosis. Beyond pulmonary improvements, ETI’s impact on sinus disease, olfactory function, and the sinonasal microbiome is just beginning to be understood. We present a contemporary review of sinonasal changes in patients with cystic fibrosis after ETI initiation.
Methods: We conducted a literature review using PubMed and Google Scholar. Articles about ETI’s impact on sinonasal disease and symptoms in patients with cystic fibrosis published in English from 2019 to August 2024 were eligible for inclusion. Studies were selected based on their contribution to understanding changes in sinus disease severity, sinonasal quality of life, olfactory function, and the sinonasal microbiome in patients with cystic fibrosis after starting ETI.
Results: An initial query yielded 41 articles. After screening abstracts, 23 articles were chosen for further review. A total of 19 articles met full inclusion and exclusion criteria. Evidence suggests ETI significantly improves sinus disease in patients with cystic fibrosis, with clinical, radiographical, and quality of life improvements observed within days to months and persisting for up to two years. Studies on olfactory changes showed mixed results, with persistent dysfunction demonstrated on psychophysical tests despite subjective improvements. ETI also alters the sinonasal microbiota, by reducing pathogenic bacteria and total bacterial load, though the clinical implications remain under investigation.
Conclusions: ETI therapy markedly improves both objective evidence of sinus disease and sinonasal quality of life in patients with cystic fibrosis. Despite some improvements in olfactory dysfunction, objective tests consistently report refractory impairment post-ETI. Changes in the sinonasal microbiome are evident, but dysbiosis remains a concern. Further research is needed to clarify the long-term effects of ETI on olfactory dysfunction and the sinonasal microbiome, especially in younger populations.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
doi:10.1001/jama.2023.8120
2. Regard L, Martin C, Da Silva J, Burgel PR. CFTR Modulators: Current Status and Evolving Knowledge. Semin Respir Crit Care Med. 2023; 44(2):186-195. doi:10.1055/s-0042-1758851
3. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine. 2019;381(19):1809-1819. doi:10.1056/NEJMoa1908639
4. Ferreira FC, Buarque CD, Lopes-Pacheco M. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor. Molecules. 2024;29(4):821. doi:10.3390/molecules29040821
5. Burgel PR, Durieu I, Chiron R, et al. Rapid Improvement after Starting Elexacaftor–Tezacaftor– Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021;204(1):64-73. doi:10.1164/rccm.202011-4153OC
6. Dreano E, Burgel PR, Hatton A, et al. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription. Eur Respir J. 2023;62(4):2300110. doi:10.1183/13993003.00110-2023
7. Zemanick ET, Taylor-Cousar JL, Davies J, et al. A Phase 3 Open-Label Study of Elexacaftor/ Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021;203 (12):1522-1532. doi:10.1164/rccm.202102-0509OC
8. Nichols DP, Morgan SJ, Skalland M, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest. 2023;133(10). doi:10.1172/JCI167957
9. McNally P, Lester K, Stone G, et al. Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/ Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial. Am J Respir Crit Care Med. 2023; 208(9):917-929. doi:10.1164/rccm.202308-1317OC
10. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-1948. doi:10.1016/S0140-6736(19)32597-8
11. International consensus statement on allergy and rhinology: rhinosinusitis 2021 - Orlandi - 2021 - International Forum of Allergy & Rhinology - Wiley Online Library. Accessed November 9, 2024. https://onlinelibrary.wiley.com/doi/10.1002/alr.22741
12. Mainz JG, Koitschev A. Pathogenesis and Management of Nasal Polyposis in Cystic Fibrosis. Curr Allergy Asthma Rep. 2012;12(2):163-174. doi:10.1007/s11882-012-0250-y
13. Kang SH, Dalcin P de TR, Piltcher OB, Migliavacca R de O. Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment. J Bras Pneumol. 2015;41(1):65-76. doi:10.1590/S1806-37132015000100009
14. Le C, McCrary HC, Chang E. Cystic Fibrosis Sinusitis. Adv Otorhinolaryngol. 2016;79:29-37. doi:10.1159/000444959
15. Ting F, Hopkins C. Outcome Measures in Chronic Rhinosinusitis. Curr Otorhinolaryngol Rep. 2018;6(3):271-275. doi:10.1007/s40136-018-0215-3
16. Chen T, Chidarala S, Young G, et al. Association of Sinonasal Computed Tomography Scores to Patient-Reported Outcome Measures: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2023;168(4):628-634. doi:10.1177/01945998221114078
17. Beswick DM, Liu CM, Overdevest JB, et al. Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis. Laryngoscope. 2024;134(9):3965-3973. doi:10.1002/lary.31438
18. Lindig J, Steger C, Beiersdorf N, et al. Smell in cystic fibrosis. Eur Arch Otorhinolaryngol. 2013;
270(3):915-921. doi:10.1007/s00405-012-2124-2
19. Miller JE, Liu CM, Zemanick ET, et al. Olfactory loss in people with cystic fibrosis: Community perceptions and impact. Journal of Cystic Fibrosis. 2023;0(0). doi:10.1016/j.jcf.2023.11.006
20. Di Lullo AM, Iacotucci P, Comegna M, et al. Cystic Fibrosis: The Sense of Smell. Am J Rhinol Allergy. 2020;34(1):35-42. doi:10.1177/1945892419870450
21. Bacon DR, Stapleton A, Goralski JL, et al. Olfaction Before and After Initiation of Elexacaftor-Tezacaftor-Ivacaftor in a Cystic Fibrosis Cohort. Int Forum Allergy Rhinol. 2022;12(2):223-226. doi:10.1002/alr.22891
22. Miller JE, Taylor-Cousar JL, Overdevest JB, et al. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. International Forum of Allergy & Rhinology. 2024;14(6):1079-1087.
doi:10.1002/alr.23312
23. DiMango E, Overdevest J, Keating C, Francis SF, Dansky D, Gudis D. Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis. Journal of Cystic Fibrosis. 2021; 20(3):460-463. doi:10.1016/j.jcf.2020.07.002
24. Tham T, Li FA, Schneider JR, et al. Functional and radiological sinonasal outcomes of CFTR modulators for sinus disease in cystic fibrosis: A meta-analysis. International Forum of Allergy & Rhinology. n/a(n/a). doi:10.1002/alr.23439
25. Stapleton AL, Kimple AJ, Goralski JL, et al. Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis. J Cyst Fibros. 2022;21 (5):792-799. doi:10.1016/j.jcf.2022.03.002
26. Shakir S, Echevarria C, Doe S, Brodlie M, Ward C, Bourke SJ. Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros. 2022;21(5):807-810. doi:10.1016/j.jcf.2022.06.003
27. Beswick DM, Khatiwada A, Miller JE, et al. Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up. J Cyst Fibros. 2024;23(2):214-218.
doi:10.1016/j.jcf.2023.09.013
28. Douglas JE, Civantos AM, Locke TB, et al. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. Int Forum Allergy Rhinol. 2021;11(2):201-203. doi:10.1002/alr.22716
29. Bode S, Rapp H, Lienert N, Appel H, Fabricius D. Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis | European Archives of Oto-Rhino-Laryngology. 2023;280.
doi:https://doi.org/10.1007/s00405-023-07859-4
30. Allgood S, Levy R, Bubaris D, Riekert K, Psoter KJ, Lechtzin N. The effect of elexacaftor/ tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis. Heliyon. 2023;9(9): e20110. doi:10.1016/j.heliyon.2023.e20110
31. Minzoni A, Mazzetti L, Orlando P, et al. Cystic fibrosis-related chronic rhinosinusitis: the key role of a comprehensive evaluation in the era of highly effective modulator therapy. Eur Arch Otorhinolaryngol. Published online August 7, 2024. doi:10.1007/s00405-024-08888-3
32. Tervo JP, DiMango E, Gudis DA, et al. Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy. International Forum of Allergy & Rhinology. 2023;13(12):2165-2171. doi:10.1002/alr.23209
33. Han EJ, Beswick DM, Eshaghian PH, et al. Decreases in Rhinology Care Utilization by People with Cystic Fibrosis on Highly Effective Modulator Therapy. Ann Otol Rhinol Laryngol. 2024;133(3): 340-344. doi:10.1177/00034894231211626
34. Miller JE, Oh E, Khatiwada A, et al. Two-Year Impact of Highly Effective Modulator Therapy on Olfactory Dysfunction. Laryngoscope. 2024; 134(6):2492-2494. doi:10.1002/lary.31447
35. Beswick DM, Humphries SM, Balkissoon CD, et al. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy. Journal of Cystic Fibrosis. 2022;21(2):e141-e147. doi:10.1016/j.jcf.2021.09.014
36. Atteih SE, Armbruster CR, Hilliam Y, et al. Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis. Pediatr Pulmonol. 2024;59(5):1266-1273. doi:10.1002/ppul.26898
37. Zemke AC, Hilliam Y, Stapleton AL, et al. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. Int Forum Allergy Rhinol. 2024;14(5):928-938. doi:10.1002/alr.23288
38. Armbruster CR, Hilliam YK, Zemke AC, et al. Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. mBio. 2024; 15(5):e0051924. doi:10.1128/mbio.00519-24
39. Hilliam Y, Armbruster CR, Rapsinski GJ, et al. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/ tezacaftor/ivacaftor therapy. Microbiol Spectr. 2024; 12(8):e0078724. doi:10.1128/spectrum.00787-24
40. Armbruster CR, Li K, Kiedrowski MR, et al. Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis. Microbiol Spectr. 2022;10(5):e0125122. doi:10.1128/spectrum.01251-22